NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Alivexis, Inc.

Alivexis, Inc.

Private
TokyoHealthcare & Life Scienceshttps://alivexis.com/

Last Round

Series D

Mar 3, 2025

Total Funding Raised

$65.1M

Company Overview

Alivexis, Inc. is a biotechnology company that merges cutting-edge drug discovery platforms with disease biology expertise to develop a portfolio of small molecule drugs.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Infrastructure

Keywords

small-molecule drug discoverycomputational drug discoverymolecular dynamics simulationin silico drug discoveryAI drug discoverytherapeutic developmentdrug discovery platformlead optimizationactive learningbiotech R&Dphysics-based modelingdrug discovery pipelinetechbiodigital drug discoveryAI-first biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alivexis, Inc. Comps

Public and private peers based on sector, stage, and business model.

Alivexis, Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Alivexis, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DMar 3, 2025
Series DJan 7, 2025
Series CMar 1, 2022
Series BMay 13, 2020
Series AAug 9, 2018

Key People

Founding team and executive leadership

S. Roy Kimura

Founder, CEO Representative Director

Founding Team

Yoh Terada

Chief Scientific Officer, Board Member

Executive Team

Alivexis, Inc. Investors

Notable investors and investment history

Alivexis, Inc. investors
InvestorRounds
JAFCO Group Co., Ltd.Series C, Series B
Keio Innovation InitiativeSeries C, Series B
Mizuho CapitalSeries B
JIC Venture Growth InvestmentsSeries D
Heights Capital ManagementSeries C
Mobile Internet CapitalSeries B
Fast Track InitiativeSeries D, Series C, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 19, 2026

    Monthly visitors increased 190% MoM, reaching 4.6K.

  • Mar 11, 2025

    Will present at the GTC 2025 japan AI day event.

Alivexis, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Alivexis, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Alivexis, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersTokyo
Employee Range12
Year Founded2016
Last FundingMar 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.